Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts
권택균, 송재민, 김인령, 박봉수, 김철훈, 정인교, 신상훈,
소속 상세정보
권택균 ( Kwon Taek-Kyun ) - Pusan National University School of Dentistry Department of Oral and Maxillofacial Surgery
송재민 ( Song Jae-Min ) - Pusan National University School of Dentistry Department of Oral and Maxillofacial Surgery
김인령 ( Kim In-Ryoung ) - Pusan National University School of Dentistry Department of Oral Anatomy and Cell Biology
박봉수 ( Park Bong-Soo ) - Pusan National University School of Dentistry Department of Oral Anatomy and Cell Biology
김철훈 ( Kim Chul-Hoon ) - Dong-A University Hospital Department of Dentistry
정인교 ( Cheong In-Kyo ) - Pusan National University School of Dentistry Department of Oral and Maxillofacial Surgery
신상훈 ( Shin Sang-Hun ) - Pusan National University School of Dentistry Department of Oral and Maxillofacial Surgery
KMID : 0355620140400060291
Abstract
Objectives:Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of bisphophonate therapy that has been reported in recent years. Osteoclastic inactivity by bisphosphonate is the known cause of BRONJ. Bone morphogenetic protein-2 (BMP-2) plays an important role in the devel-opment of bone. Recombinant human BMP-2 (rhBMP-2) is potentially useful as an activation factor for bone repair. We hypothesized that rhBMP-2 would enhance the osteoclast-osteoblast interaction related to bone remodeling.
Materials and Methods: Human fetal osteoblast cells (hFOB 1.19) were treated with 100 μM alendronate, and 100 ng/mL rhBMP-2 was added. Cells were incubated for a further 48 hours, and cell viability was measured using an MTT assay. Expression of the three cytokines from osteoblasts, receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), and macrophage colony-stimulating factor (M-CSF), were analyzed by real-time polymerase chain reaction and enzyme-linked immunosorbent assay.
Results:Cell viability was decreased to 82.75%±1.00% by alendronate and then increased to 110.43%±1.35% after treatment with rhBMP-2 (P<0.05, respectively). OPG, RANKL, and M-CSF expression were all decreased by alendronate treatment. RANKL and M-CSF expression were increased, but OPG was not significantly afected by rhBMP-2.
Conclusion:rhBMP2 does not affect OPG gene expression in hFOB, but it may increase RANKL and M-CSF gene expression.
키워드
Bone morphogenetic protein-2; Alendronate; Osteoblasts; Macrophage colony-stimulating factor; RANK ligand
원문 및 링크아웃 정보
등재저널 정보